Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1994-4-8
|
pubmed:abstractText |
Forty-five male patients with planned coronary artery bypass operation were randomized in a double blind fashion to receive either 6 million kallikrein inactivator units of aprotinin (high-dose group), 2 million kallikrein inactivator units of aprotinin (low-dose group), or placebo (control group). Postoperative bleeding was significantly decreased in both aprotinin groups in comparison to that in the control group (590 ml [290 to 1800 ml] high-dose group and 650 ml [280 to 1900 ml] low-dose group versus 920 ml (350 to 2700 ml) control group, p < 0.001). There was no difference between the two aprotinin groups. The need for postoperative blood transfusion was significantly lower in the aprotinin groups (1.46 [0 to 4] blood units high-dose group and 1.65 [0 to 5] blood units low-dose group versus 2.43 [0 to 7] blood units control group, p < 0.05). All patients underwent coronary angiography between the seventh and twelfth postoperative day. No difference was found among the three groups in patency of vein grafts-93.8% in the high-dose group, 94.5% in the low-dose groups, and 93.3% in the control group. Therefore, aprotinin significantly reduced postoperative bleeding and transfusion requirement after coronary artery bypass grafting without influencing early graft patency.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0022-5223
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
107
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
807-10
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7510351-Aprotinin,
pubmed-meshheading:7510351-Blood Transfusion,
pubmed-meshheading:7510351-Coronary Angiography,
pubmed-meshheading:7510351-Coronary Artery Bypass,
pubmed-meshheading:7510351-Double-Blind Method,
pubmed-meshheading:7510351-Graft Occlusion, Vascular,
pubmed-meshheading:7510351-Hemorrhage,
pubmed-meshheading:7510351-Humans,
pubmed-meshheading:7510351-Male,
pubmed-meshheading:7510351-Middle Aged,
pubmed-meshheading:7510351-Postoperative Complications,
pubmed-meshheading:7510351-Time Factors
|
pubmed:year |
1994
|
pubmed:articleTitle |
Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood.
|
pubmed:affiliation |
Second Department of Surgery, University Hospital of Vienna, Austria.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|